Education
About Us
Working with TipRanks
Follow Us
Vera Therapeutics (VERA)
NASDAQ:VERA
VERA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$18.53 - $51.61
Previous CloseN/A
Volume142.65K
Average Volume (3M)953.06K
Market Cap
$1.43B
Enterprise Value$1.97B
Total Cash (Recent Filing)$92.65M
Total Debt (Recent Filing)$54.64M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
May 08, 2025EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.74
Shares Outstanding63,771,720
10 Day Avg. Volume1,413,713
30 Day Avg. Volume953,061
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)883.47
Price to Cash Flow (P/CF)-11.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-13.53
Forecast
1Y Price Target
$67.20Price Target Upside199.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsVera Therapeutics announced the completion of full enrollment for the Phase III ORIGIN 3 study, evaluating the safety and efficacy of atacicept in IgAN patients.
Market OpportunityThere is a large commercial opportunity in IgAN, with multiple winners expected in the BLyS and/or APRIL inhibitor class due to the disease-modifying potential of these treatments.
Product DifferentiationAtacicept is the only BLyS and/or APRIL inhibitor studied as a self-administered injection in both Phase II and III studies, with 90% patient retention at 2 years.
Bears Say
Competitive PressureVera experienced a significant sell-off following competitor Otsuka's announcement about their plans to file for a competing treatment.
Regulatory RiskThere is regulatory risk and uncertainty regarding Otsuka’s strategy for sibeprenlimab, which impacts the competitive landscape.
---
Ownership Overview
13.61% Insiders
15.97% Mutual Funds
0.10% Other Institutional Investors
56.63% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VERA FAQ
What was Vera Therapeutics’s price range in the past 12 months?
Vera Therapeutics lowest stock price was $18.53 and its highest was $51.61 in the past 12 months.
What is Vera Therapeutics’s market cap?
Vera Therapeutics’s market cap is $1.43B.
When is Vera Therapeutics’s upcoming earnings report date?
Vera Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 24 days.
How were Vera Therapeutics’s earnings last quarter?
Vera Therapeutics released its earnings results on Mar 20, 2025. The company reported -$0.72 earnings per share for the quarter, beating the consensus estimate of -$0.812 by $0.092.
Is Vera Therapeutics overvalued?
According to Wall Street analysts Vera Therapeutics’s price is currently Undervalued.
Does Vera Therapeutics pay dividends?
Vera Therapeutics does not currently pay dividends.
What is Vera Therapeutics’s EPS estimate?
Vera Therapeutics’s EPS estimate is -0.73.
How many shares outstanding does Vera Therapeutics have?
Vera Therapeutics has 63,771,720 shares outstanding.
What happened to Vera Therapeutics’s price movement after its last earnings report?
Vera Therapeutics reported an EPS of -$0.72 in its last earnings report, beating expectations of -$0.812. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vera Therapeutics?
Currently, no hedge funds are holding shares in VERA
---
Vera Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.20 (199.60% Upside)
$67.20 (199.60% Upside)
Blogger Sentiment
Bullish
VERA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 73.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 5.8%
Last 30 Days ▲ 5.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.05%
12-Months-Change
Fundamentals
Return on Equity
-44.83%
Trailing 12-Months
Asset Growth
273.96%
Trailing 12-Months
Company Description
Vera Therapeutics
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
---
VERA Stock 12 Month Forecast
Average Price Target
$67.20
▲(199.60% Upside)
Technical Analysis
Travere Therapeutics
―
Disc Medicine
―
Kymera Therapeutics
―
Immunocore Holdings
―
NewAmsterdam Pharma Company
―
Best Analysts Covering VERA
1 Year
1 Year Success Rate
6/15 ratings generated profit
1 Year Average Return
+94.15%
reiterated a buy rating last month
Copying Anupam Rama's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +94.15% per trade.
---